CMB International Global Markets | Equity Research | Sector Update

China Technology

Implications of Texas Instruments 3Q23: weaker industrial, destocking and slower China recovery

Texas Instruments (TI) reported in-line 3Q23 results but weaker 4Q23 guidance. 3Q revenue declined 14% YoY to US\$4.5bn and EPS dropped 25% YoY, mainly due to weakness across segments except auto business. Looking into 4Q23E, mgmt. expects industrial segment weakness to broaden and post-pandemic recovery in China is weaker-than-expected, while automotive growth will continue. Overall, we expect inventory destocking and margin pressure for global analog semi will persist into 4Q23E, while automotive segment is the only bright spot driven by EV/ADAS demand. For stocks, we believe rising inventory and pricing pressure for non-auto analog will continue to weigh on domestic analog names in the near term, such as SG Micro (300661 CH) and 3Peak (688536 CH), while we expect resilient auto demand in 2H23E will benefit component names with rising auto exposure, such as BYDE (285 HK), FIT Hon Teng (6088 HK), and BOEVx (710 HK).

- 3Q23 mostly in-line; broad weakness ex-auto. By segment, industrial/ comm. segments were down MSD/upper-teens QoQ, while PE/automotive/enterprise segments were up 20%/MSD/upper-SD QoQ. 3Q GPM came in at 62.1%, down 690bps YoY, below consensus, dragged by lower utilization, higher costs from fab expansion and reduced factory loadings. Inventory value was up US\$ 179mn QoQ to US\$ 3.9bn with inventory days down 2 days QoQ to 205 days, given better production control and inventory destocking.
- 4Q23E guidance miss; industrial weakness broadening and weaker China recovery. Mgmt. guided 4Q23E revenue range of US\$ 3.93-4.27bn and EPS range of US\$ 1.35-1.57, both of which missed market consensus of US\$4.42bn/US\$1.79. Mgmt. expected lower utilization due to weaker demand (especially industrials) and elevated inventory levels into 4Q23E. We believe lower utilization and higher depreciation for new fabs will continue to put pressure on TI's revenue and margins. Mgmt. maintained US\$ 5bn annual CapEx guidance for FY23-26E despite industry headwinds.
- Weaker recovery and pricing pressure to weigh on domestic analog names; Resilient auto demand is positive to component players. Walking into analog industry downturn for five consecutive quarters, we see little sign of sales recovery in the near term given inventory destocking and weakening demand. Yet, the pace of recovery for different downstream industries (industrial/PE/comm./auto) varied and led to a mixed sales outlook. We stay selective on stocks and we believe domestic analog names may remain under pressure in near term, while we prefer component names with share gain, auto exposure and domestic substitution trends, such as BYDE (285 HK), FIT Hon Teng (6088 HK), and BOEVx (710 HK).

Valuation Table

Name	Ticker	Rating	Mkt Cap (USD mn)	Price (LC)	TP (LC)	P/E FY23E	``	P/B (x) FY23E	FY24E
BYDE	285 HK	BUY	10,428	36.20	45.30	20.0	15.9	2.7	2.4
FIT Hon Teng	6088 HK	BUY	997	1.07	2.06	7.1	5.7	0.4	0.4
BOEVx	710 HK	BUY	633	6.26	21.53	7.2	5.8	0.5	0.4
Texas Instruments	TXN US	NR	128,484	141.47	NA	19.5	19.8	7.8	7.2
Analog Devices	ADI US	NR	80,199	160.94	NA	16.0	19.0	2.3	2.3
SG Micro	300661 C⊦	I NR	5,263	82.40	NA	73.0	47.0	10.0	8.3
3Peak	688536 CH	I NR	2,436	148.32	NA	61.2	35.8	4.4	3.9

Source: Company data, CMBIGM estimates



OUTPERFORM (Maintain)

China Technology Sector

Alex NG (852) 3900 0881 alexng@cmbi.com.hk

Claudia LIU claudialiu@cmbi.com.hk

Related Reports:


- Implications of TSMC 3Q23: cycle nearing the bottom; Positive on smartphone/PC supply chain -24 Oct 2023 (link)
- Implications of ASML/LAM Research 3Q23 results - 20 Oct 2023 (<u>link</u>)
- Implications of US's updated chip export restrictions to global/ domestic SPE/GPU companies - 18 Oct 2023 (link)
- Global SPE 2Q23 Wrap: China demand remains resilient; Awaiting upcycle after 2023 slowdown - 18 Sep 2023 (<u>link</u>)
- Global fabless/IDM 2Q23 wrap: expect continued inventory correction for non-Al players; All eyes on NVDA 3Q23E guidance – 23 Aug 2023 (link)
- Global foundry 2Q23 Wrap: prolonged inventory correction; slower demand recovery in 2H-16 Aug 2023 (link)




Figure 1: Texas Instruments' 3Q23 results review

TI (TXN US)	Actual	Consensus			
US\$ mn	FY3Q23	FY3Q22	YoY (%)	FY3Q23E	Diff (%)
Revenue	4,532	5,241	-14%	4,553	0%
Gross Profit	2,815	3,617	-22%	2,864	-2%
Operating Profit	1,892	2,678	-29%	1,923	-2%
Net Profit	1,709	2,295	-26%	1,687	1%
EPS (cent US\$)	1.85	2.47	-25%	1.84	1%
GPM	62.1%	69.0%	-6.9 ppt	62.9%	-0.8 ppt
OPM	41.7%	51.1%	-9.4 ppt	42.2%	-0.5 ppt
NPM	37.7%	43.8%	-6.1ppt	37.0%	0.7 ppt


Source: Bloomberg, Company data, CMBIGM






Source: Bloomberg, CMBIGM estimates






Source: Bloomberg, CMBIGM estimates

Figure 3: TI's GPM and NPM trends



Source: Bloomberg, CMBIGM estimates

Figure 5: TI revenue by region (9M23)



Source: Bloomberg, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratin	gs
BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM
OUTPERFORM MARKET-PERFORM UNDERPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM or any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, receiver that CMBIGM may a condition of interst that could affect the objective of the polycetive of the report and the OMBIGM and the avance at that could affect the objective of the polycetive of the report of the Definition of the polycetive of the companies in this report. As a result, receiver the could affect the objective of the report and the OMBIGM and the other that combines that could affect the objective of the polycetive of the report of the objective of the report of the report

this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analysts is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.